Show submenu

Test for COVID-19 on DBS

Created 05/12/2020 14:03

COVID-19 Banner

An IgG DBS test for SARS-CoV-2

With support from the Norwegian Research Council, Vitas has developed and validated an IgG serology test for covid-19 in Dried Blood Spots (DBS). The test shows excellent performance (>94% sensitivity and 99.9 % specificity (n= 601). The test includes a CE IVD marked DBS collection kit as well as a CE IVD marked ELISA assay using spike protein S1 as antigen. An extended validation in 1000 individuals was completed 1. Juli 2020. The purpose was to test the assay in routine, get feedback from users on user friendliness and investigate the rate of infection among these 1000 subjects. 50 SARS-CoV-2 PCR positive volunteers are submitting DBS for IgG repeated measurements. From this we will learn at what rate IgG levels are reduced over time.

Upcoming vaccines and application of the IgG DBS test

The test Vitas has applied to the DBS platform detects IgG antibodies against the spike protein S1 critically important for the binding to human cells thereby allowing transfer into the cells and replication of virus. Most covid-19 vaccines are based on developing just antibodies against the S1 protein. Thus, the Vitas’ DBS covid-19 test is a very good way to evaluate the response to vaccines given to large populations. This type of testing will probably be essential as a marker of developed immunity against covid-19.